【药明康德】11亿美元囊获抗纤维化疗法勃林格殷格翰达成合作bristolmyerssquibbreceiveseuropeancommissionapprovalforzeposia(ozanimod)forthetreatmentofadultpatientswithrelapsingremittingmultiplesclerosiswithactivedisease参考来源：blueprintmedicinesannounceseuropeanmedicinesagencyvalidationofmarketingauthorizationapplicationforavapritinibforthetreatmentofpdgfrαd842vmutantgistandfourth-linegist
|创新rnai疗法获fda突破性疗法认定治疗遗传性肝脏疾病在所有剂量组中，大多数患者疾病得到控制，orr为7.1%，dcr为76.2%。中位疾病稳定时间为4.2个月。中位pfs为4.0个月，中位os为10.1个月。在39例可获得基线后数据患者中，有18例患者肿瘤缩小。沃利替尼全球首个新药上市申请获国家药监局受理